Introduction
Tumour pathogenesis and the mechanisms of underlying apoptosis in tumour cells have been widely studied. A close correlation between the effects of chemotherapeutic agents and inactivation of apoptotic pathways has been observed, 1, 2 and most chemotherapeutic agents appear to work by inducing apoptosis in tumour cells. With regard to apoptotic pathways, the p53-BAX mitochondrial apoptosis pathway plays an important role in maintaining cell stability. 3 -5 In a previous study, genes that lie upstream (such as the cyclin-dependent DAC induces apoptosis in cholangiocarcinoma cells kinase 6 The potential to reverse DNA methylation may provide a new target for clinical antineoplastic treatment.
The molecule 5-aza-2-deoxycytidine (DAC) is an effective inhibitor of methyltransferase. 7 The present study examined the effect of DAC on growth of the human cholangiocarcinoma QBC939 cell line in order to determine its mechanism of action with a view to elucidating new targets for improving cholangiocarcinoma treatment.
Materials and methods

QBC939 CELL CULTURE
The QBC939 cell line is derived from human cholangiocarcinoma. 8 The cells used in the present study were a generous gift from Dr Shu-Guang Wang (The Third Military Medical University, Chongqing, China). The QBC939 cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and penicillin (100 000 U/l), and incubated at 37°C in 5% carbon dioxide in a humidified environment.
THE EFFECTS OF DAC ON CELL PROLIFERATION
The effects of DAC on QBC939 cell proliferation were assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were cultured as described above until they were in log phase growth. 
EXAMINATION OF CELL MORPHOLOGY IN RESPONSE TO DAC TREATMENT
The QBC939 cells were cultured and a single cell suspension was generated, as described above. The cells were divided into two groups: a control group (cultured cells without DAC) and a group to which 5 µmol/l of DAC was added. The cells were incubated for 72 h at 37°C in 5% carbon dioxide. Morphological alterations that resulted from DAC treatment were observed using transmission electron microscopy (TEM 
ANALYSIS OF GENE PROMOTER METHYLATION BY METHYLATION-SPECIFIC PCR
To evaluate the extent of the methylation of target gene promoter regions, QBC939 cells were incubated for 72 h at 37°C in 5% carbon dioxide, with or without DAC 5 µmol/l. For each experimental condition, 5 × 10 6 cells were used to extract genomic DNA using the QIAamp DNA Micro Kit (Qiagen, Hilden, Germany), following the manufacturer's instructions. The quantity of DNA was calculated by the A 260/280 ratio. The methylation status of the target genes was examined using a methylation-specific polymerase chain reaction (PCR) method. Briefly, 1 µg DNA solution was extracted from the QBC939 cells, as described above, and treated with urea/bisulphite according to a previously described method 9 to change unmethylated cytosines to uracils. The modified DNA was resuspended in 20 µl of TE buffer (10 mM Tris-HCl, 1 mM ethylenediaminetetra-acetic acid [EDTA]; pH 8.0) and immediately subjected to PCR or stored at -20°C. Table 1 shows the primer sequences used for PCR (Hokkaido Bioscience Company, Hokkaido, Japan). The PCR reaction was carried out in a 20-µl reaction volume containing 1 U of Hot Start Ex Taq™ DNA polymerase (Takara, Shiga, Japan), 2 µl of 10 × Ex Taq™ buffer (Takara), 2 µl of deoxyribonucleotide triphosphate mixture and 8 pmol of each primer, and 1 µl of DNA template. The cycling programme involved preliminary denaturation at 96°C for 3 min, followed by 40 cycles of denaturation at 96°C for 30 s, annealing at 60°C for 30 s, and elongation at 72°C for 30 s, followed by a final elongation step at 72°C for 4 min. In vitro methylated DNA (Intergen Health, Brooklyn, NY, USA) was used as a positive control for methylation. DNA from normal Methylation-specific polymerase chain reaction (PCR) primer sequences, annealing temperature, and amplification product size used for the current study assessing the mechanism of 5-aza-2-deoxycytidine on growth of the human cholangiocarcinoma QBC939 cell line DAC induces apoptosis in cholangiocarcinoma cells lymphocytes was used as a negative control and water was used as an overall negative control. For each experimental sample, 5 µl of PCR product was analysed by 1% Tris/Borate/EDTA gel electrophoresis and visualized using ethidium bromide staining and ultraviolet light. Each methylationspecific PCR was repeated at least three times.
FLOW CYTOMETRY ANALYSIS OF CHANGE IN APOPTOSIS AND CELL CYCLE
Untreated negative control QBC939 cells and cells treated with DAC 5 µmol/l were incubated for 72 h at 37°C in 5% carbon dioxide before harvesting. In total, 1 × 10 6 cells/ml were used for each experimental condition. Cells were harvested using 0.25% trypsin for 4 h and washed twice with 1 mM phosphate-buffered saline, pH 7.4. Ethanol (70%) was precooled at 4°C for 30 min and then added drop by drop to permeabilize the cell membrane. The cells were subsequently stained with 15% propidium iodide at 4°C for 20 -30 min. The cell cycle and apoptosis rate were detected by flow cytometry (FACSort™; BD Biosciences, San Jose, CA, USA).
Results
Analysis of cell proliferation using the MTT assay showed that treatment with DAC markedly inhibited the growth of QBC939 cells in dose-and time-dependent manners (Fig. 1) . The half maximal inhibitory concentration of DAC at 72 h was 5 µmol/l.
The morphological changes that occurred in response to DAC treatment were examined. Following DAC treatment (5 µmol/l for 72 h), the QBC939 cells exhibited pyknosis, basophilic cytoplasm and an abundance of dense nuclear chromatin compared with untreated cells. The nuclear membrane of DAC-treated cells could not be observed, and nuclear chromatin clustered in the centre of the nucleus during cell division. TEM revealed that treated cells had diminished microvilli, darkened electron density, lipid droplets, less endocytoplasmic reticulum, aggregated (Figs 2 and 3) .
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Methylation-specific PCR demonstrated that the promoter regions of the tumour suppressor genes CDKN2A and DAPK1 in QBC939 cells were methylated in untreated cells and demethylated following DAC treatment (Fig. 4) .
Treatment of QBC939 cells with DAC 5 µmol/l for 72 h induced cell-cycle arrest at the G 0 /G 1 , S and G 2 /M phases. Flow cytometry analysis demonstrated that the rate of apoptosis of QBC939 cells was greatly enhanced (43.04%) relative to that of untreated cells (4.31%) (Fig. 5) .
Discussion
Cholangiocarcinoma is a malignant tumour of the epithelial bile duct that accounts for 3% of malignant tumours of the gastrointestinal tract. 10, 11 In recent years, the incidence and mortality rate of cholangiocarcinoma have been increasing. 12, 13 The mean age of patients diagnosed with cholangiocarcinoma is 50 years, and the incidence in males is 1.5 times greater than in females. 14 -16 Without specific clinical manifestations and tumour markers, the early diagnosis and treatment of cholangiocarcinoma is very difficult. Although surgery can relieve obstruction of the biliary tract, the distinct pathobiology of cholangiocarcinoma makes it difficult to achieve a successful surgical outcome. Thus, chemotherapy may have an important role in combined therapy. To date, however, there are few studies that suggest that chemotherapeutic agents can be effective for the treatment of cholangiocarcinoma. 17, 18 Treatment with DAC has been shown to induce demethylation of the PYCARD (ASC/TMS1) gene of the p53-BAX mitochondrial apoptosis pathway in colon cancer cells, via tumour molecule intervention. 19 Moreover, transfection of colon cancer cells with the wild-type TP53 gene increased their rate of apoptosis and sensitivity to chemotherapy. 19 Thus, DAC These results suggested that the p53-BAX mitochondrial apoptosis pathway is important for tumourigenesis and the regulation of cancer-cell sensitivity to chemotherapy. Overall, the results of that study indicated that the reversible character of DNA methylation might be a useful new strategy for treating cholangiocarcinoma. Treatment with DAC inhibited the growth of QBC939 cells in the present study, and the effect was dose-and time-dependent. Apoptosis of DAC-treated cells was observed using TEM analysis. Flow cytometric analysis demonstrated that the apoptosis rate of QBC939 cells treated with DAC was greatly enhanced, relative to that of cells not treated with DAC.
Other studies have suggested that the observed inhibition may result from the demethylation effect of DAC on p53-BAX mitochondrial apoptosis pathway gene promoters. 20, 21 The features of DNA methylation in malignant tumours include tumour specificity, gene and tissue specificity, and reversibility. 22 -24 DAC is an effective methyltransferase inhibitor. Studies have shown that low doses of DAC (0.1 and 0.5 µmol/l) can cause tumour cell differentiation by demethylation and subsequent re-expression of a gene controlling differentiation. 25, 26 The hypermethylation of the promoters of p53-BAX mitochondrial apoptosis pathway genes was analysed in the present study, both before and after treatment with DAC. The tumour suppressor genes CDKN2A and DAPK1 in QBC939 cells were methylated before treatment with DAC and Mammalian cells have the capacity to modify their genomes epigenetically via the covalent addition of a methyl group to the five position of the cytosine ring, within the context of a CpG dinucleotide. 27 Certain regions of the genome, which often are clustered at the 5′ end of genes, possess the expected CpG frequency and have been termed CpG islands. CpG island methylation has been shown to be essential for normal development, X chromosome inactivation, imprinting and the suppression of parasitic DNA sequences. 28 Hypermethylation of CpG islands can, however, cause the inactivation of gene expression. 29, 30 Research has shown that either upstream (CDKN2A, DAPK1) or downstream (PYCARD, TP53) genes of the p53-BAX mitochondrial apoptosis pathway can become silenced by methylation and lead to inactivation of the pathway. 6 Demethylation by DAC has been used successfully in the treatment of leukaemia and myelodysplastic syndrome. 31, 32 The present study demonstrated that DAC could induce apoptosis of QBC939 cells by reactivation of hypermethylated p53-BAX mitochondrial apoptosis genes in cholangiocarcinoma cells. Thus, the reversible character of DNA methylation may be a useful new strategy for treating cholangiocarcinoma.
